Release Date: 2024-05-28

Novel Therapies in High-Risk Non-Muscle Invasive Bladder Cancer

Furkan Sendogan (Author), Meftun Culpan (Author)

Release Date: 2024-05-28

The management of high-risk non-muscle-invasive bladder cancer(NMIBC) presents a significant challenge to many physicians, due to the ability of the disease to resist intravesical BCG therapy and the substantial rate of progression to the muscle-invasive bladder cancer. In the current literature, the alternative treatment modality for patients with BCG-unresponsive bladder cancer is radical cystectomy, which [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Management of Non-Muscle Invasive Bladder Cancer
First Page155
Last Page167
DOIhttps://doi.org/10.69860/nobel.9786053359197.13
ISBN978-605-335-919-7 (PDF)
LanguageENG
Page Count13
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

The management of high-risk non-muscle-invasive bladder cancer(NMIBC) presents a significant challenge to many physicians, due to the ability of the disease to resist intravesical BCG therapy and the substantial rate of progression to the muscle-invasive bladder cancer. In the current literature, the alternative treatment modality for patients with BCG-unresponsive bladder cancer is radical cystectomy, which has a significant impact on the quality of life. In addition, the global shortage of BCG, which has become more apparent in recent years, has increased the necessity for new treatments. In this book chapter, we discussed new and current treatment modalities in high-risk NMIBC.

Furkan Sendogan (Author)
Assistant Professor, Bahcesehir University
https://orcid.org/0000-0001-6865-018X
3Furkan Şendoğan has been employed as an assistant professor at the Istanbul Bahçeşehir Faculty of Medicine, Department of Urology. He concurrently serves as a physician at the urology clinic at Istanbul Medicana Çamlıca Hospital. His work has led to the publication of over 50 research articles, oral and poster presentations, book chapters and reviews. The majority of his research activities focus on uro-oncology, endourology, urinary tract stone disease and urinary tract infections. He is also closely attuned to developments in endourological and robotic surgical procedures.

Meftun Culpan (Author)
Associate Professor, Uskudar University
https://orcid.org/0000-0001-8573-1192
3Meftun Çulpan has been employed as an associated professor of urology at Uskudar University, Faculty of Medicine, Department of Urology. He concurrently serves as a physician at the urology clinic at Istanbul Memorial Ataşehir Hospital. He has more than 40 original research articles and more than 100 oral or poster presentations. He continues his academic studies especially in the field of uro-oncology.

  • Musat MG, Kwon CS, Masters E, Sikirica S, Pijush DB, Forsythe A. Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR). ClinicoEconomics and Outcomes Research. 2022;14:35–48.

  • Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol 2024;211(4):533–8.

  • Gontero P, Birtle A, Compérat E, Dominguez JL, Liedberg F, Mariappan P, et al. Non-muscle-invasive Bladder Cancer (TaT1 and CIS) EAU Guidelines on. 2024.

  • Brausi M, Oddens J, Sylvester R, Bono A, Van De Beek C, Van Andel G, et al. Side effects of bacillus calmette-guérin (BCG) in the treatment of intermediateand high-risk Ta, T1 papillary carcinoma of the bladder: Results of the EORTC genito-urinary cancers group randomised phase 3 study comparing onethird dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65(1):69–76.

  • Perera M, Papa N, Christidis D, McGrath S, Manning T, Roberts M, et al. The impact of the global bacille Calmette–Guérin shortage on treatment patterns: population-based data. BJU Int 2018;121(2):169–72.

  • Cookson MS, Herr HW, Zhang Z-F, Soloway S, Sogani PC, Fair WR. The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome. J Urol 1997;158(1):62–7.

  • Lebacle C, Loriot Y, Irani J. BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know? World J Urol 2021;39(11):4037–46.

  • Cao X, Fu Y-X, Peng H. Promising Cytokine Adjuvants for Enhancing Tuberculosis Vaccine Immunity. Vaccines (Basel) 2024;12(5):477.

  • O’DONNELL MA, KROHN J, DeWOLF WC. Salvage intravesical therapy with interferon-α2b plus low dose bacillus calmette-guerin is effective in patients with superficial bladder cancer in whom bacillus calmette-guerin alone previously failed. J Urol 2001;166(4):1300–5.

  • O’Regan T, Tatton M, Lyon M, Masters J. The effectiveness of BCG and interferon against non-muscle invasive bladder cancer: a New Zealand perspective. BJU Int 2015;116(S3):54–60.

  • Shepherd AR, Shepherd E, Brook NR. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Cochrane Database of Systematic Reviews 2017;2017(3).

  • Gray GR, Ribi E, Granger D, Parker R, Azuma I, Yamamoto K. Brief Communication: Immunotherapy of Cancer: Tumor Suppression and Regression by Cell Walls of Mycobacterium phlei Attached to Oil Droplets2. J Natl Cancer Inst. 1975;55(3):727–30.

  • Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, et al. Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-Guérin. J Urol 2015;193(4):1135–43.

  • Li R, Amrhein J, Cohen Z, Champagne M, Kamat AM. Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients. Bladder Cancer 2017;3(1):65–71.

  • Noble S, Goa KL. Gemcitabine. Drugs 1997;54(3):447–72.

  • Jones G, Cleves A, Wilt TJ, Mason M, Kynaston HG, Shelley M. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews 2012;

  • Di Lorenzo G, Perdonà S, Damiano R, Faiella A, Cantiello F, Pignata S, et al. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer. Cancer 2010;116(8):1893–900.

  • Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz H-J, Lee CT, et al. SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin. J Urol 2013;190(4):1200–4.

  • Kuperus JM, Busman RD, Kuipers SK, Broekhuizen HT, Noyes SL, Brede CM, et al. Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer. Urology 2021;156:191–8.

  • Djafari AA, Javanmard B, Razzaghi M, Hojjati SA, Razzaghi Z, Faraji S, et al. Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Randomized Controlled Trial. Urol J 2023;20(2):123–8.

  • Grimberg DC, Shah A, Inman BA. Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. Eur Urol Focus 2020;6(4):620–2.

  • Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, et al. Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study. J Urol 2023;209(5):890–900.

  • van der Heijden MS, Cutie C, Acharya M, Stromberg K, Li X, Beeharry N, et al. 719TiP SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy. Annals of Oncology 2021;32:S723–4.

  • Roumiguié M, Black PC. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non–muscle-invasive bladder cancer: Pro. Eur Urol Focus 2022;8(4):1117–20.

  • Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, et al. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. Eur Urol Oncol 2023;6(5):531–4.

  • McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT, et al. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-GuérinNaïve High-Risk Nonmuscle-Invasive Bladder Cancer. J Urol 2022;208(3):589–99.

  • McElree IM, Steinberg RL, Mott SL, O’Donnell MA, Packiam VT. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer. JAMA Netw Open 2023;6(2):e230849.

  • Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH, et al. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus 2023;9(4):561–3.

  • Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol 2017;8.

  • https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.

  • Balar A V, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22(7):919–30.

  • Necchi A, Roumiguié M, Kamat AM, Shore ND, Boormans JL, Esen AA, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2024;25(6):720–30.

  • Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, et al. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncology 2020;16(10):507–16.

  • Meghani K, Cooley LF, Choy B, Kocherginsky M, Swaminathan S, Munir SS, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. Eur Urol 2022;82(6):602–10.

  • Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, et al. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol 2023;84(6):536– 44.

  • Al-Khami AA, Youssef S, Abdiche Y, Nguyen H, Chou J, Kimberlin CR, et al. Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther 2020;19(10):2105–16.

  • Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, et al. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer. Future Oncology 2024;20(14):891–901.

  • De Santis M, Abdrashitov R, Hegele A, Kolb M, Parker S, Palou Redorta J, et al. A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). J Clin Oncol. 2019;37(7_suppl):TPS500–TPS500.

  • Knudson KM, Hodge JW, Schlom J, Gameiro SR. Rationale for IL-15 superagonists in cancer immunotherapy. Expert Opin Biol Ther 2020;20(7):705–9.

  • Chamie K, Chang SS, Gonzalgo M, Kramolowsky E V., Sexton WJ, Bhar P, et al. Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). J Clin Oncol. 2022;40(16_suppl):4508–4508.

  • O’donnell Ma, Lıllı K, Leopold C. Interım Results From A Natıonal Multıcenter Phase II Trıal Of Combınatıon Bacıllus Calmette-Guerın Plus Interferon Alfa-2b For Superfıcıal Bladder Cancer. J Urol 2004;172(3):888–93.

  • Yamashita M, Rosser CJ, Zhou J-H, Zhang X-Q, Connor RJ, Engler H, et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 2002;9(8):687–91.

  • Connor RJ, Anderson JM, Machemer T, Maneval DC, Engler H. Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: A study in rats evaluating dosing regimens. Urology 2005;66(1):224–9.

  • Benedict WF, Tao Z, Kim C-S, Zhang X, Zhou J-H, Adam L, et al. Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein. Molecular Therapy 2004;10(3):525–32.

  • Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021;22(1):107–17.

  • https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-adenoviral-vector-based-gene-therapy-high-risk-bacillus-calmette-guerin.

  • Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results. Urol Oncol. 2018;36(10):440–7.

  • Li R, Steinberg GD, Uchio EM, Lamm DL, Shah P, Kamat AM, et al. CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). J Clin Oncol. 2022;40(16_suppl):4597–4597.

  • Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res 2004;24(5C):3295–301.

  • Giguère CM, Bauman NM, Sato Y, Burke DK, Greinwald JH, Pransky S, et al. Treatment of Lymphangiomas With OK-432 (Picibanil) Sclerotherapy. Arch Otolaryngol Head Neck Surg 2002;128(10):1137.

  • Bandari J, Zummo J, Belani K, Brown E, Metcalf M, Nanayakkara N. Phase 1a/b safety study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer (ADVANCED-1). J Clin Oncol. 2022;40(16_ suppl):TPS4620–TPS4620.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!